What Альфа Д3-Тева treats: main uses and benefits

Альфа Д3-Тева (alfacalcidol) is a prescribed medication commonly used in situations involving certain distressing symptoms in contexts where the body requires additional symptomatic support for bone and mineral function. It is relevant in contexts involving heightened systemic burden, where the medication is applied across therapeutic domains where additional symptomatic support is needed.

Supporting Bone Health in Kidney Disease

This medication is commonly used across conditions presenting with acute episodes, such as renal osteodystrophy (bone changes caused by kidney failure). It helps address symptom clusters like bone pain and muscle weakness, and generally provides supportive relief when symptoms interfere with routine activities.

Addressing Bone Softening and Deformities

Альфа Д3-Тева is applied across therapeutic domains where additional symptomatic support is needed for bone softening and structural weakness, such as rickets and osteomalacia. It is relevant for managing symptoms that interfere with daily comfort, and may assist with maintaining functional stability.

Stabilizing Calcium and Hormone Imbalances

It is often used when symptoms intensify due to abnormal levels of calcium in the blood. This supports patients during episodes of heightened discomfort, and generally assists with maintaining functional stability.

---

Common Symptom Addressed: Bone Pain

Who Can and Cannot Use Альфа Д3-Тева?

The official eligibility profile for Альфа Д3-Тева (Alfacalcidol) is defined by absolute contraindications and mandatory conditional use rules derived from government regulatory labeling.

Contraindications (Who Must Not Use)

Category	Non-Eligibility Condition
Metabolic Status	Hypercalcaemia (high calcium levels) or Hypervitaminosis D (Vitamin D overdose).
Hypersensitivity	Known allergy to alfacalcidol or any component, including arachis oil or soya.
Comorbidity	Metastatic Calcification or concurrent use with digitalis glycosides if hypercalcaemia is present.

---

Conditional and Restricted Use

Eligibility is conditional for certain populations, requiring close clinical supervision and caution:

• Renal Impairment: Patients with kidney disease are a primary approved group but require ongoing, regular monitoring of serum calcium and kidney function.
• Other Comorbidities: Use requires caution in patients with granulomatous diseases (e.g., sarcoidosis), arteriosclerosis, or a history of nephrolithiasis (kidney stones).

Age and Life Stage Eligibility

• Age Groups: Use is generally established and permitted across the entire age spectrum, from neonates to older adults, when indicated for specific mineral disorders.
• Pregnancy and Lactation: Use is not recommended during pregnancy and breastfeeding, due to the risk of fetal/infant harm from altered maternal calcium levels.

Interactions with other medicines and products

The interaction profile for Alfacalcidol focuses on substances that affect systemic mineral balance or alter the medicine's systemic exposure. The official documentation identifies several key interaction patterns based on regulatory classification.

Contraindicated and Restricted Combinations

Classification	Interacting Substance(s)	Official Constraint Statement
Contraindicated	Digitalis Glycosides (e.g., Digoxin)	Co-administration is formally contraindicated in the presence of hypercalcaemia due to an increased risk of cardiac arrhythmias.
Restricted Use	Other Vitamin D Analogues (e.g., Calcitriol)	Should not be given concurrently due to an enhanced risk of hypercalcaemia.
Restricted Use	Magnesium-containing Antacids/Laxatives	Should not be used during treatment due to the increased risk of hypermagnesaemia.

---

Pharmacokinetic and Pharmacodynamic Interactions

The co-administration of certain medicines may lead to alterations in serum levels. Anticonvulsants (e.g., Phenytoin, Barbiturates) are documented to have enzyme-inducing effects that result in an increased metabolism of Alfacalcidol, affecting its exposure profile.

Pharmacodynamic interactions primarily involve substances that share an effect on calcium homeostasis, leading to potential additive effects. For example, Thiazide Diuretics and Calcium-containing Preparations may increase the risk of developing hypercalcaemia. Conversely, Glucocorticoids may decrease Alfacalcidol’s therapeutic efficacy by inhibiting intestinal calcium absorption.

Administration Timing Requirements

Certain preparations require mandated separation to maintain efficacy. Bile Acid Sequestrants (e.g., Cholestyramine) may impair absorption. Official labeling requires Alfacalcidol to be administered at least 1 hour before, or 4 to 6 hours after the intake of the sequestrant to mitigate this risk. In addition, Alfacalcidol may increase the serum concentration of aluminium when co-administered with Aluminium-containing Preparations.

Reliable Hormone D Activation and Bypass

Alfacalcidol acts as a prodrug characterized by a hydroxyl group at the 1alpha-position. This structural feature defines its activation pathway: it undergoes rapid conversion primarily in the liver via the enzyme 25-hydroxylase into the active metabolite, Calcitriol (1,25-dihydroxyvitamin D3). This metabolic process bypasses the tightly regulated renal hydroxylation step, ensuring activation independently of kidney function.

---

VDR Modulation and Mineral Metabolism Regulation

Calcitriol functions as a high-affinity agonist for the intracellular Vitamin D Receptor (VDR). VDR activation, and complex formation with RXR, initiates gene transcription in target cells. In the intestinal mucosa, this stimulates the synthesis of calcium-binding proteins, leading to enhanced absorption of both calcium and phosphorus from the digestive tract.

---

Endocrine Control and Muscular Function

The systemic VDR-agonism includes direct suppression of the synthesis and secretion of Parathyroid Hormone (PTH) in the parathyroid glands. At the renal level, it promotes tubular reabsorption of calcium. The collective increase in circulating minerals provides the substrate necessary for osteoid mineralization. Furthermore, direct VDR action in skeletal muscle supports regeneration of muscle fibers, contributing to the restoration of muscle tone.

Official Administration Guidelines for Альфа Д3-Тева (Alfacalcidol)

The administration of this medication is oral, typically taken once daily, and the dosage must be carefully individualized and titrated by a healthcare provider.

Dosing and Monitoring Protocol

The initial daily dose is determined based on the patient's age and weight, and the precise dose should be prescribed by a physician.

Patient Group	Initial Dose	Administration Instruction
Adults and Adolescents (>20 kg)	1 mcg per day	Swallow capsule whole with fluid.
Elderly	0.5 mcg per day	May be sufficient.
Children (<20 kg)	0.05 mcg/ kg per day	Individualized dose adjustment is mandatory.

Following the initiation of therapy, the dose must be adjusted by the prescribing physician according to the patient's biochemical response, specifically focusing on avoiding hypercalcemia.

Key Procedural Steps and Constraints:

1. Ingestion: The soft capsules are to be swallowed whole with a sufficient amount of fluid; they may be taken with or without food.
2. Monitoring Frequency: Plasma levels of calcium, phosphate, and alkaline phosphatase must be monitored regularly. During the initial dose-titration phase, plasma calcium levels are typically measured at weekly intervals. Once the dose is established, monitoring frequency may be reduced to every 2 to 4 weeks.
3. Dose Adjustment: If hypercalcemia occurs, treatment must be stopped immediately until plasma calcium levels return to normal (approximately one week). Treatment is then typically resumed at half the previous dose.
4. Missed Dose: If a dose is missed, patients should take the next scheduled dose at the usual time. They must not take a double dose to compensate for the missed one.

This medication requires strict adherence to a physician-titrated dosage, making ongoing laboratory monitoring of key mineral levels the central component of the administration protocol.

Research evidence / Overview of studies for Alfacalcidol

Evidence for Use in Kidney-Related Bone Disease (Renal Osteodystrophy)

Studies exploring the approach to bone and mineral disorders associated with chronic kidney failure frequently employ Randomized Controlled Trials (RCTs) to assess outcomes. Research examined the use of Alfacalcidol in adults with chronic kidney disease, including those on maintenance hemodialysis. Observed data show patterns related to the maintenance of serum calcium and phosphate levels and the evolution of Parathyroid Hormone (PTH) levels over time in observed populations.

However, long-term evidence remains limited for certain endpoints. Research explored the association between the intervention and hard clinical outcomes, such as all-cause mortality and major cardiovascular events; findings were mixed, and subgroup findings are uncertain.

---

Research Exploring Use in Bone Softening Conditions (Rickets and Osteomalacia)

For rare metabolic disorders like rickets and osteomalacia, the evidence base largely relies on accumulated clinical literature and long-term observational data. The research, evaluated in adults and children, monitored outcomes related to physical discomfort and clinical signs of bone health. Data describes patterns observed in the studies, including changes related to structural bone features in children with rickets and the evolution of bone softness indicators in adults with osteomalacia.

---

Research Exploring Parathyroid Hormone and Mineral Imbalances (Hypoparathyroidism)

Controlled studies have investigated the medicine's association with stabilizing serum calcium and phosphate levels in patients with Hypoparathyroidism. The studies report how outcomes related to systemic or functional imbalance evolved in the observed populations, with data showing patterns related to calcium and phosphate concentrations.

The evidence was studied for its association with fractures and falls. However, findings are limited and often based on subgroup data or studies where the medicine was observed in studies as part of a combination treatment, indicating that certainty remains low for independent outcomes in this area. Additional controlled studies are noted as needed by regulatory bodies.

Common questions about Альфа Д3-Тева (FAQ)

---

Q: Is Альфа Д3-Тева the same as regular Vitamin D?

Official documents describe the active ingredient, Alfacalcidol, as a synthetic derivative of Vitamin D3. While regular Vitamin D is typically activated in the kidneys, Alfacalcidol is designed to bypass this step. It is converted into the body's active Vitamin D hormone, Calcitriol, primarily in the liver.

---

Q: Why is Альфа Д3-Тева prescribed instead of other Vitamin D supplements?

The primary rationale for prescribing this medicine is its ability to be activated independently of kidney function. The regulatory mechanism bypasses the crucial activation step that normally occurs in the kidneys. This design allows the medicine to function as intended, especially when kidney health is impaired, which is vital for treating specific metabolic disorders.

---

Q: Is Альфа Д3-Тева considered a hormone or a vitamin?

Officially, the medicine is classified as a Vitamin D analogue, meaning it is a synthetic compound similar to Vitamin D. However, it functions as a 'pro-drug' for Calcitriol, which is the fully active Vitamin D hormone naturally produced in the body.

---

Q: Is it normal to feel a bit nauseous when first starting Альфа Д3-Тева?

Nausea is listed in the official documents as an uncommon adverse reaction. Importantly, it is also a non-specific symptom associated with developing hypercalcemia, which is abnormally high calcium levels in the blood. If nausea is experienced, especially alongside other symptoms like increased thirst or headache, these signs are often indicators that the patient's calcium levels may need to be checked by a healthcare provider.

---

Q: Can Альфа Д3-Тева interact with my blood pressure medicine?

Yes, official product information documents list known interactions with certain types of blood pressure medication. Specifically, a class of drugs known as Thiazide diuretics is known to increase the risk of developing hypercalcemia when used concurrently with Alfacalcidol.

---

Q: Can elderly patients use Альфа Д3-Тева without special monitoring?

Official documents indicate that use in all patient populations, including older adults, requires ongoing, frequent monitoring of blood mineral levels. This monitoring, which checks calcium and phosphate levels, is essential to quickly identify and help manage the risk of hypercalcemia.

---

Q: What are the signs that I might be experiencing a serious side effect from Альфа Д3-Тева?

The most clinically significant safety risk is hypercalcemia (abnormally high calcium levels). Signs of developing this condition include non-specific symptoms such as headache, fatigue, nausea, vomiting, increased thirst, and frequent urination. Regulatory documents note that these signs may indicate a need for prompt monitoring by a healthcare professional.

---

Q: What are the long-term effects of taking Альфа Д3-Тева?

The primary concern with long-term use is the risk associated with prolonged, uncorrected high calcium levels. Regulatory documents indicate that persistent hypercalcemia carries a risk of serious complications, including potential kidney stone formation (nephrolithiasis) and soft tissue calcification (calcinosis).

---

Q: Does Альфа Д3-Тева interact with antacids or medicines for heartburn?

Yes, interactions are documented with certain stomach medicines. Antacids containing magnesium may increase the risk of hypermagnesaemia, while preparations containing aluminum may increase aluminum serum concentration. Disclosure of all concurrent preparations to a healthcare provider is noted to be important when taking this medicine.

---

Q: Is there a known interaction between Альфа Д3-Тева and corticosteroids?

Yes, official documents list a known pharmacodynamic interaction. Glucocorticoids, a type of corticosteroid, may potentially decrease the medicine’s overall therapeutic effect by inhibiting calcium absorption in the intestine.

---

Q: Why is it important to know if I have parathyroid issues before taking Альфа Д3-Тева?

The medicine is officially used to manage conditions like Hypoparathyroidism, which involves parathyroid gland dysfunction. The drug’s mechanism involves suppressing Parathyroid Hormone (PTH) secretion. Therefore, pre-existing parathyroid issues are central to the appropriate use and necessary monitoring protocols for this treatment.

---

Q: What information should I share with my other doctors about taking Альфа Д3-Тева?

Official labeling stresses that all prescribing healthcare providers should be aware that the patient is taking Alfacalcidol. This allows them to avoid prescribing contraindicated or interacting medicines, such as certain diuretics or heart medications like Digitalis. Additionally, awareness of the requirement for regular mineral level monitoring is crucial.

---

Q: What are the components of Альфа Д3-Тева besides the main active ingredient?

Official product documentation explicitly lists the active ingredient (Alfacalcidol) and the other components, known as excipients. For some formulations, these components include ingredients like arachis oil (peanut oil) and soya, which are noted as potential allergens and contraindications for hypersensitive patients.

---

Q: What is the difference between Alpha-D3 Teva and calcitriol?

Official documents explain that Alfacalcidol is the pro-drug for the active hormone, Calcitriol (1,25-dihydroxyvitamin D3). This means Alfacalcidol is converted into the active Calcitriol primarily in the liver once it is in the body.

---

Q: How long does it typically take to see a noticeable change after starting Альфа Д3-Тева?

While the exact onset of action is not explicitly stated in regulatory documents, the initial monitoring protocol suggests that critical changes occur quickly. Official guidelines mandate that plasma calcium levels must be checked at weekly intervals during the initial dose-titration phase until the patient's level is stable.

---

Q: Can I take other vitamin supplements while I am on Альфа Д3-Тева?

Co-administration with other Vitamin D analogues (including Calcitriol) is formally restricted by regulatory bodies. This is due to the enhanced and dangerous risk of developing hypercalcemia. It is generally advisable to inform a healthcare provider about all concurrent vitamin or mineral supplements.

---

Q: Are there different strengths of Альфа Д3-Тева available?

Yes. The official product information confirms that the medicine is generally manufactured in a range of strengths for different dosing requirements. These may include 0.25 mu g, 0.5 mu g, and 1.0 mu g soft capsules or oral solutions.

---

Q: Is Альфа Д3-Тева used to treat osteoporosis?

While the medicine addresses conditions related to bone health, official regulatory indications are specific to metabolic and secondary bone disorders. These include osteomalacia (bone softening) and bone disease related to kidney failure, but osteoporosis is not explicitly listed as a primary indication in the product labeling.

---

Q: Does this medicine contain lactose or gluten?

Regulatory documents explicitly list all non-active components (excipients). While the product is often free of gluten, some capsule formulations may contain lactose. It is recommended to check the specific product leaflet or packaging for the exact excipients in the prescribed formulation.

---

Q: Can Альфа Д3-Тева affect my sleep?

Official safety information does not specifically list sleep disturbances (insomnia or sleepiness) as an adverse reaction. However, non-specific symptoms of hypercalcemia, such as fatigue and headache, may indirectly impact sleep quality.

---

Q: How quickly does the body process and eliminate Альфа Д3-Тева?

Pharmacokinetic studies summarized in regulatory documents describe the processing speed of the active metabolite, Calcitriol. It is typically eliminated from the body with a half-life described as being between approximately 3 to 6 hours.

---

Q: Does sun exposure affect how Альфа Д3-Тева works?

The medicine is a synthetic analogue designed to bypass the body’s natural Vitamin D activation steps. Because it is a highly active form that does not rely on the skin's response to sunlight, the mechanism is not expected to be significantly reliant on or affected by sun exposure.

---

Q: Is Альфа Д3-Тева used for all types of vitamin D deficiency?

No. The official indications are specific to metabolic and bone disorders where the body’s normal ability to activate Vitamin D is impaired, such as chronic kidney disease (renal osteodystrophy) and hypoparathyroidism. It is not typically used for simple, general Vitamin D deficiency.

---

Q: Does taking Альфа Д3-Тева require me to change my diet significantly?

Regulatory information indicates that it is sometimes necessary to monitor or control the intake of calcium and phosphate in the diet. This is a safety measure intended to help prevent hypercalcemia (high blood calcium) from developing while on this treatment.

Official Storage and Disposal Requirements

Storage & Disposal Scope
Labeled Storage Temperature Requirements: Store at a temperature not exceeding 25 C.
Light/Moisture Protection Requirements: The product must be protected from light and stored with the container tightly closed to protect from moisture.
Packaging-Related Storage Rules: Keep the medicine in its original container or packaging to maintain stability.
Child-Protection Storage Requirements: Keep this medicine out of the sight and reach of children.
Disposal Instructions: Do not throw away unused or expired medicine via household waste or wastewater. Dispose of the product according to local and national pharmaceutical waste regulations, typically by returning it to a designated pharmacy or collection point.

---

Connection to the Overall Storage/Disposal Profile

Regulatory documents define that the product must be stored below 25 C and be protected from environmental factors like light and moisture to maintain its stability until the expiration date. The official profile mandates that the medicine must remain inaccessible to children. Disposal instructions explicitly forbid environmental contamination by prohibiting disposal in the household trash or down the drain, requiring proper pharmaceutical waste handling.